



European Monitoring Centre
for Drugs and Drug Addiction

PROGRAMME

Annual expert meeting on Drug-related deaths (DRD) and Drug-related infectious diseases (DRID)

16–18 October 2013
Lisbon

Annual expert meeting on Drug-related deaths (DRD) and Drug-related infectious diseases (DRID)

Objectives

- To assess and discuss recent developments on DRD and DRID in Europe, including:
 - Recent findings of European mortality cohort studies and monitoring of drug-induced deaths;
 - DRID strategy review and HIV outbreak risk assessment follow-up;
- To convene the DRID and DRD expert networks for information exchange and stimulating new initiatives.

Day 1 – Wednesday, 16 October 2013

Conference Centre

09.00 **Welcome** — Chairs: Julián Vicente and Alexis Goosdeel, EMCDDA

Brief civil society address — Luis Mendão, Civil Society Forum on HIV/AIDS

Conference Centre

Room CdS 106

09.30 **DRID Plenary** — Chair: Julián Vicente, EMCDDA

- Introduction, meeting objectives and overview of DRID activities — Lucas Wiessing, EMCDDA
- HIV outbreak in Greece, results of the Aristotle study — Vana Sypsa, Greece
- Important differences in injecting risks between people who inject drugs in eastern and western Europe — Mait Raag, Estonia
- Burden of HCV disease in Finland — Mika Salminen, Finland

DRD Workshop 1: Mortality cohort studies: EU pooled analyses and other longitudinal studies — Chair: Janusz Sieroslawski, Poland

- Discussion of the main findings of the nine pooled cohort studies – way forward — Marko Markus, Croatia, Marcis Trapencieris, Latvia, Roberto Debono, Malta, Guus Cruts, Netherlands, Thomas Clausen, Norway, Janusz Sieroslawski, Poland, Carmelia Matache, Romania, Jozica Selb, Slovenia, Noelia Lloren, Spain, EMCDDA
- Amphetamine users study: overall and cause specific mortality — Marcis Trapencieris, Latvia

Room CdS 107

DRD Workshop 2: Medicine-related deaths: a focus on tramadol and fentanyl — Chairs: Klaudia Palczak and João Matias, EMCDDA

- Fentanyl: trendspotting overview and focus on deaths — Jane Mounteney, EMCDDA
- Update on fentanyl national trends — John Corkery, United Kingdom, Gleb Denissov, Estonia, Erkki Vuori, Finland and Joakim Stranberg, Sweden
- Medicines in the context of the Early warning system (EWS): legal requirements under the Council Decision and Pharmacovigilance — Michael Evans-Brown, EMCDDA
- Tramadol-related deaths: Situation in the United Kingdom — John Corkery, United Kingdom
Results of the 2013 survey — João Matias, EMCDDA

11.00 Coffee break

Day 1 – Wednesday, 16 October 2013

	Conference Centre	Room CdS 107
11.30	<p>DRID Plenary — Chair: Lucas Wiessing, EMCDDA</p> <ul style="list-style-type: none"> EMIS results on MSM in Spain – new drugs and sexual risks of HIV — Cinta Folch, Spain Incidence of drug injection: systematic review and meta-analysis of cohort studies among at-risk populations — María José Bravo and Blanca Iciar Indave, Spain DRID strategy review, presentation of expert meeting results — Lucas Wiessing, EMCDDA Panel discussion on the strategy review expert meeting results followed by introduction to the workshops (30–40 min) 	<p>DRD Workshop 3: Enhanced monitoring of acute emergencies: focus on cannabis/cannabinoids — Chair: Isabelle Giraudon, EMCDDA</p> <ul style="list-style-type: none"> Update on national cannabis-related emergencies: continuous increase — Noelia Llorens, Spain National Trends: Eva Januševičienė, Lithuania, Henrik Saelen, Denmark, Viktor Mravčík, Czech Republic, Esther Croes, The Netherlands Barcelona: experience of acute drug-related poisoning monitoring — Antonia Domingo-Salvany, Spain
		<p>Room CdS 106</p> <p>DRD Workshop 4: Underestimation and cross-validation of drug-induced deaths data — Chair: Danica Thanki, EMCDDA</p> <ul style="list-style-type: none"> Monitoring drug-induced deaths in Turkey — Bulent Sam, Turkey DRD underestimation, overestimation, biases in reporting? — Anne-Claire Brisacier, France Monitoring drug-induced deaths in Slovakia — Jozef Sidlo, Slovakia
13.00	Lunch	
	Different rooms	Conference Centre
14.00	<p>DRID workshop 1: Monitoring HBV vaccination through the existing EMCDDA data system — Mario Cruciani, Italy (Room CdS 106)</p> <p>DRID workshop 2: Burden of HCV disease — Mika Salminen, Finland (Room CdS 107)</p> <p>DRID workshop 3: Capacity building and feedback to service providers, networking of experts — Anastasios Fotiou, Greece and Frédéric Denecker, EMCDDA (Room CdS 012)</p> <p>DRID workshop 4: Diagnostic testing prevalence data — Catharina Mathei, Belgium and Magdalena Rosińska, Poland (Room PAL 102)</p>	<p>DRD Plenary: Overview of 2013 activities and discussion of new developments at national level Chairs: Julián Vicente, EMCDDA and Erkki Vuori, Finland</p> <ul style="list-style-type: none"> Objectives of the 2013 meeting: Key indicators progress and work in progress — Isabelle Giraudon, EMCDDA Drug-induced deaths reported in 2013: preliminary results for discussion — João Matias, EMCDDA What is causing the increase in DRDs in Ireland? — Suzi Lyons, Ireland Enhancing toxicovigilance of new drugs (including reporting of deaths) — Michael Evans-Brown, EMCDDA NPS-related deaths – a tool for prospective monitoring? 4-MA and 5-IT examples — Isabelle Giraudon, EMCDDA Feedback received from countries and discussion Feedback and discussion on cohorts workshop (1 national expert rapporteur)
15.30	Coffee break	

Day 1 – Wednesday, 16 October 2013

	Different rooms	Conference Centre
16.00	<p>DRID workshop 5: Reporting and use of subnational data, categorising and grading data, reporting burden — Eleni Kalamara, Sandrine Sleiman and André Noor, EMCDDA (Room CdS 012)</p> <p>DRID workshop 6: Monitoring other infections (TB, HAV, STIs, spore-forming bacteria, MRSA) — Hans Blystad, Norway (Room CdS 106)</p> <p>DRID workshop 7: Using TDI data for DRID/DRID study in treatment centres — María Jose Bravo, Spain and Julián Vicente, EMCDDA (Room CdS 107)</p> <p>DRID workshop 8: Non-IDUs, other groups (steroid users, MSM who use drugs) — Vivian Hope, United Kingdom (Room PAL 102)</p>	<p>DRD Plenary: Overview of 2013 activities and discussion of new developments at national level (continued) — Chairs: Isabelle Giraudon, EMCDDA and John Corkery, United Kingdom</p> <ul style="list-style-type: none"> • Feedback and discussion on DRD cross-validation studies, acute emergencies and medicine-related deaths workshops (3 national experts rapporteurs) • Follow-up study: Adherence rate to OST — Charlotte Klein, Austria • Developments in the Norwegian overdose situation — Thomas Clausen, Norway
17.30	Cocktail	

Day 2 – Thursday, 17 October 2013

Conference Centre: **Joint Plenary DRD–DRID**09.00 **Mortality cohort studies among drug users** — Chairs: Marica Ferri, EMCDDA and Viktor Mravčík, Czech Republic

- Mortality cohort study NIQUAD — Tim Millar, United Kingdom
- French study: preliminary findings of the 2013 record linkage — Anne-Claire Brisacier, France
- Overview and main findings of the pooled EU cohorts — Isabelle Giraudon, EMCDDA
- Pooled EU cohorts – implications of age differences in mortality — Marcis Trapencieris, Latvia

10.30 Coffee break

11.00 **Mortality related to infection – HIV, anthrax: service provision and guidelines** — Chairs: María José Bravo, Spain and Vivian Hope, United Kingdom

- Estimation of HIV mortality related to IDU — Isabelle Giraudon, EMCDDA
- Mortality trends in PLHIV in Latvia and insight from cohort studies — Anda Karnīte and Marcis Trapencieris, Latvia
- Ten year trends in HIV and service provision in Europe — Martin Busch, Austria

Anthrax prevention

- ECDC/EMCDDA Joint anthrax prevention guidance for PWID — Cornelius Bartels, ECDC

13.00 Lunch

Conference Centre

Room CdS 107

14.00 **Parallel session: Hepatitis C infection in PWID** — Chairs: Magdalena Rosińska, Poland and Mika Salminen, Finland

- Incidence of hepatitis C infection among people injecting drugs in the EU (with a focus on the UK) — Katelyn Cullen and Vivian Hope, United Kingdom
- All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years — Knut Kielland, Norway
- Hep C initiative — Eberhard Schatz, Netherlands
- EMCDDA HCV treatment for prevention project in Scandinavia and Belgium – short activities update — Teodora Groshkova, EMCDDA

Parallel session: Harm related to new psychoactive drugs and methamphetamine — Chairs: Isabelle Giraudon, EMCDDA and Gergely Horvath, Hungary

- Establishing the Acute Harms associated with the use of new psychoactive substances: what is available, deficiencies in current datasets, potential for poisons centre data, Euro-DEN data collection — David Wood, United Kingdom
- Trends in recreational drug-related deaths, including new psychoactive substances — John Corkery, United Kingdom
- 2013 Trendspotter meeting on methamphetamines: main findings, main concerns — Jane Mounteney, EMCDDA

15.30 Coffee break

Conference Centre: **Joint Plenary DRD–DRID**16.00 **Prevention of overdose and infection** — Chairs: Dagmar Hedrich and Teodora Groshkova, EMCDDA

- Improvement in the recognition and assessment of acute drug toxicity in the pre-hospital environment — Paul Dargan, United Kingdom
- Pre-provision of naloxone to prevent heroin overdose deaths: evidence, myths and UK experience — John Strang, United Kingdom
- Prevention of overdose and infection. Experience from Villa Maraini Foundation/Italian Red Cross/International Federation Red Cross Red Crescent (IFRC) — Fabio Patrino, Italy
- State of play of the 2003 Council Recommendation on the prevention and reduction of health-related harm: focus on trends in DRD and responses — Charlotte Klein, Austria

17.30 End of the regular DRD–DRID meeting, closure — Chairs: Isabelle Giraudon and Lucas Wiessing, EMCDDA

Day 3 – Friday, 18 October 2013

This day is an extension of the DRD–DRID meeting focused on the countries at risk of HIV outbreaks. Participants from days 1 and 2 interested in attending are welcome, but this is not required and given the large number of DRD and DRID participants it is encouraged that those only marginally interested might prefer not to attend.

Conference Centre

09.00 **HIV Risk assessment** — Chairs: Lucas Wiessing, EMCDDA and Anastasios Fotiou, Greece

Objectives:

1. To discuss outcomes and implications of the recent EMCDDA–ECDC risk assessment;
2. To present the project ‘HIV outbreaks among PWID in Europe – linking economic, epidemiological and service provision data’ and discuss the feasibility of launching an information collection exercise at national level;
3. To exchange information on latest developments and possible collaborative support to countries.

- Introduction and objectives — Lucas Wiessing, EMCDDA
- EMCDDA–ECDC updated joint EU risk assessment 2013 — Dagmar Hedrich, EMCDDA
- The impact of the economic downturn on HIV among drug users in Europe – a conceptual framework — Anastasios Fotiou, Greece
- HIV outbreaks among PWID in Europe – linking economic, epidemiological and service provision data — Claudia Storti, EMCDDA
- Discussion

10.30 Coffee break

11.00 **Two parallel workshops** with short (5–10 min.) country presentations and discussion

Room CdS 107

Country updates group 1 — Moderator: Claudia Storti, EMCDDA

- Greece — Anastasios Fotiou
- Romania — Andrei Botescu
- Hungary — Anna Tarján
- Bulgaria — Violeta Bogdanova
- Turkey — Elif Mutlu
- Cyprus — Nasia Fotsiou
- Portugal — Domingos Duran

Conference Centre

Country updates group 2 — Moderator: Lucas Wiessing, EMCDDA

- Latvia — Anda Karnīte
- Estonia — Maris Salekešin
- Lithuania — Valerij Dobrovolskij
- Poland — Marta Struzik
- Slovakia — Silvia Slezáková and Zuzana Alexandercikova
- United Kingdom — Vivian Hope

12.30 Lunch

Conference Centre

13.30 Feedback from sessions, general discussion, including agreements and preparations for follow-up — Chairs: Claudia Storti, EMCDDA and Andrei Botescu, Romania

15.00 End of the meeting, closure — Chairs: Claudia Storti and Lucas Wiessing, EMCDDA